ArticleHuman vaccines & immunotherapeutics2025
Adult pertussis in the acellular-cell vaccine era: Comparative analysis of pertussis toxin antibodies in hospitalized patients with prolonged cough.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A controlled human infection model for symptomatic pertussis in North America using the pertactin-producing clinical isolate D420.medRxiv : the preprint server for health sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past two years, pertussis cases in China have reemerged, shifting from infants to older children (≥6 years). In adults, underdiagnosis is common due to symptom overlap with other cough disease and limited testing, highlighting the need for better assessment in prolonged cough cases. Residual serum samples from 589 adults hospitalized with prolonged cough (≥2 weeks) formed the case group, while 589 age-, sex-, and region-matched non-cough patients served as controls. PT-IgG levels, measured via ELISA, indicated past (≥62.5 IU/mL) or recent infection (≥100 IU/mL, within a year). PT-IgG ≥ 62.5 IU/mL was detected in 17.0% of cases vs. 2.7% of controls, and ≥100 IU/mL in 7.3% vs. 1.0%. Cases had a higher median PT-IgG (16.74 vs. 2.50 IU/mL,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.